SCHEMBL6397751

SCHEMBL6397751

O=P(O)(O)Oc1cccc(O)c1C(O)CCCc1ccc(O)cc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.39
SGMS1 Q86VZ5 1/20 0.39
SGMS2 Q8NHU3 1/20 0.39
INPPL1 O15357 1/20 0.39
INPP5B P32019 1/20 0.39
INPP5A Q14642 1/20 0.39
HTR2A P28223 1/20 0.36
TRPV1 Q8NER1 1/20 0.35
FDFT1 P37268 1/20 0.35
PLK1 P53350 1/20 0.35
IGF1R P08069 1/20 0.34
ALOX15 P16050 1/20 0.34
CALM1 P0DP23 1/20 0.33
CYP19A1 P11511 1/20 0.33
AKR1B10 O60218 1/20 0.33
AKR1B1 P15121 1/20 0.33
SLC28A3 Q9HAS3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6401939 0.94 INPPL1 (0.40) ACHESGMS1SGMS2INPPL1INPP5B
SCHEMBL6403447 0.88 MGLL (0.38) INPPL1INPP5BINPP5AFDFT1CALM1
SCHEMBL6397106 0.87 INPPL1 (0.42) INPPL1INPP5BINPP5AHTR2ATRPV1
SCHEMBL6398906 0.85 SLC28A3 (0.42) ACHESGMS1SGMS2IGF1RALOX15
SCHEMBL6397757 0.81 ANPEP (0.40) INPPL1INPP5BINPP5AHTR2A
SCHEMBL6399784 0.81 ACHE (0.42) ACHESGMS1SGMS2TRPV1FDFT1
SCHEMBL6396309 0.79 SLC28A3 (0.46) ACHESGMS1SGMS2INPPL1INPP5B
SCHEMBL6396051 0.79 ACHE (0.46) ACHESGMS1SGMS2INPPL1INPP5B
SCHEMBL6398009 0.79 SLC28A3 (0.38) ACHESGMS1SGMS2INPPL1INPP5B
SCHEMBL6399779 0.78 ACHE (0.39) ACHESGMS1SGMS2TRPV1FDFT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ACHE 4868/4885SGMS1 3968/4885SGMS2 4314/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 ACHE 4865/4885SGMS1 4101/4885SGMS2 4281/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ACHE 4868/4885SGMS1 3968/4885SGMS2 4314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.